Study Of Correlation Between The Plasma Visfatin Levels And Type 2 Diabetes And Impaired Glucose Tolerance

ObjectiveTo investigate the change of plasma visfatin level and the relationship of plasma visfatin level to metabolic and biochemical indicators in the subjects with different glucose tolerances, and the influence of rosiglitazone on plasma visfatin level.MethodsFasting plasma visfatin levels were measured by enzyme-linked immunosorbent assay in 30 cases of type 2 diabetes mellitus(T2DM), 23 cases of impaired glucose tolerance(IGT)and 31 normal control(sNC). Meanwhile fasting true insulin(FTI), fasting plasma glucose(FPG), blood lipid, hemoglobin A1c(HbA1c), creatinine, uric acid and blood pressure, height, weight, waistline, hip circumference were measured, and body mass index(BMI), waist to hip ratio(WHR) and homeostasis model of insulin resistance(HOMA-IR)were also calculated. The correlation between the plasma visfatin level and the metabolic and biochemical indicators was analyzed by SPSS 12.0 software for window. After rosiglitazone therapy (4mg/d) was given to the patients with IGT for 3 months, some of the above mentioned indicators were measured again and the plasma visfatin levels in the pre-& post-treatment patients with IGT was compared.ResultsThe plasma visfatin levels in T2DM patients were remarkably higher than those in IGT patients and CN(p<0.01 or p<0.05) and the plasma visfatin levels in patients with IGT were remarkably higher than those in NC(p=0.001). the level of visfatin in obese T2DM patients was significantly higher than that in non-obese T2DM patients(p=0.005). A correlation analysis showed that the serum visfatin levels was positively correlated with BMI, WHR, FTI, HOMA-IR respectively(p<0.01). In a multiple linear regression analysis, WHR and HOMA-IR was independently associated with plasma visfatin level. After the rosiglitazone therapy for 3 months, plasma visfatin level significantly increased in post-treatment patients with IGT compared to pre-treatment patients with IGT(p=0.029).ConclusionThe fasting plasma visfatin levels in T2DM and IGT groups increased and fasting plasma visfatin level is positively related to obesity and insulin resistant; post-rosiglitazone treated patients with IGT showed significant increases in serum visfatin compared to pre-rosiglitazone treatment, therefore visfatin may contribute to the pathogenesis of T2DM, obesity and insulin resistant; and PPARγagonist may prevent T2DM by regulating adipocytokines including visfatin.